GUANFACINE EXTENDED RELEASE IN THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS

被引：13
作者：
Connor, D. F. [1 ]
Rubin, J. [2 ]
机构：
[1] Univ Connecticut, Sch Med, Farmington, CT 06030 USA
[2] Shire Dev Inc, Wayne, NJ USA
来源：
DRUGS OF TODAY | 2010年 / 46卷 / 05期
关键词：
POSTTRAUMATIC-STRESS-DISORDER; DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; OPPOSITIONAL DEFIANT; TOURETTES-SYNDROME; CONDUCT DISORDER; CONTROLLED-TRIAL; BLOOD-PRESSURE; OPEN-LABEL; HEART-RATE;
D O I：
10.1358/dot.2010.46.5.1450095
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Extended-release guanfacine (Intuniv(TM)) is a novel long-acting, once-daily formulation of guanfacine indicated for attention deficit hyperactivity disorder (ADHD) in 6 to 77 year old children and adolescents. In doses 1 to 4 mg/day, guanfacine extended release (GXR) significantly improves the symptoms of inattention and hyperactivity-impulsivity in ADHD youngsters compared with placebo. Because of different pharmacokinetics, GXR is not substitutable on a mg-for-mg basis with immediate release guanfacine. Although extended release guanfacine does not demonstrate clinically significant ECG changes, mild slowing of the heart rote and some lowering of SBP and DBP does occur and requires vital sign monitoring during treatment. Children with a clinically significant cardiovascular history are not eligible for GXR therapy. Future research is exploring GXR effectiveness in ADHD complicated by oppositional defiant symptoms, ADHD complicated by tic disorders, posttraumatic stress disorders, and impulsive aggression in ADHD youngsters.
引用
收藏
页码：299 / 314
页数：16
相关论文
共 80 条
[1]  
[Anonymous], DIAGN STAT MAN MENT
[2]  
ARNSTEN AFT, 1988, J NEUROSCI, V8, P4287
[3]  
Arnsten AFT, 1996, ARCH GEN PSYCHIAT, V53, P448
[4]   Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Emerging concepts from new data [J].
Arnsten, Amy F. ;
Scahill, Lawrence ;
Findling, Robert L. .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2007, 17 (04) :393-406
[5]   Toward a New Understanding of Attention-Deficit Hyperactivity Disorder Pathophysiology An Important Role for Prefrontal Cortex Dysfunction [J].
Arnsten, Amy F. T. .
CNS DRUGS, 2009, 23 :33-41
[6]   Stress signalling pathways that impair prefrontal cortex structure and function [J].
Arnsten, Amy F. T. .
NATURE REVIEWS NEUROSCIENCE, 2009, 10 (06) :410-422
[7]   Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD [J].
Barkley, RA .
PSYCHOLOGICAL BULLETIN, 1997, 121 (01) :65-94
[8]   Attention-deficit/hyperactivity disorder: A selective overview [J].
Biederman, J .
BIOLOGICAL PSYCHIATRY, 2005, 57 (11) :1215-1220
[9]   Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD [J].
Biederman, J ;
Faraone, SV ;
Milberger, S ;
Jetton, JG ;
Chen, L ;
Mick, E ;
Greene, RW ;
Russell, RL .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1996, 35 (09) :1193-1204
[10]   Attention-deficit hyperactivity disorder [J].
Biederman, J ;
Faraone, SV .
LANCET, 2005, 366 (9481) :237-248
12345678